{"id":113688,"date":"2026-09-22T23:50:26","date_gmt":"2026-09-22T23:50:26","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/rosen-national-trial-lawyers-encourages-unicycive-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-uncy\/"},"modified":"2026-09-22T23:50:26","modified_gmt":"2026-09-22T23:50:26","slug":"rosen-national-trial-lawyers-encourages-unicycive-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-uncy","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/rosen-national-trial-lawyers-encourages-unicycive-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-uncy\/","title":{"rendered":"ROSEN, NATIONAL TRIAL LAWYERS, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – UNCY"},"content":{"rendered":"

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE)<\/a> — <\/p>\n

WHY:<\/strong> Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the \u201cClass Period\u201d), of the important November 2, 2026 lead plaintiff deadline.<\/strong><\/p>\n

SO WHAT:<\/strong> If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.<\/p>\n

WHAT TO DO NEXT:<\/strong> To join the Unicycive class action, go to https:\/\/rosenlegal.com\/cases\/unicycive-therapeutics-inc\/join<\/a> or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com<\/a> for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026.<\/strong> A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n

WHY ROSEN LAW: <\/strong>We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases.<\/strong> Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs\u2019 Bar. Many of the firm\u2019s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n

DETAILS OF THE CASE: <\/strong>According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and\/or failed to disclose that: (1) Unicycive had not inspected its third-party manufacturing vendor\u2019s facility or otherwise audited the facility\u2019s compliance with current good manufacturing practices; (2) as a result, Unicycive lacked a reasonable basis to believe that the vendor had resolved the U.S. Food and Drug Administration\u2019s (\u201cFDA\u201d) cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor\u2019s facility\u2019s manufacturing practices; (4) as a result of the foregoing, the regulatory approval of oxylanthanum carbonate (\u201cOLC\u201d) was reasonably likely to be delayed; and (5) as a result of the foregoing, defendants\u2019 positive statements about Unicycive\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n

To join the Unicycive class action, go to https:\/\/rosenlegal.com\/cases\/unicycive-therapeutics-inc\/join<\/a> or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com<\/a> for information on the class action.<\/p>\n

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor\u2019s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n

Follow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n

——————————-<\/p>\n

Contact Information:<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Laurence Rosen, Esq.
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Phillip Kim, Esq.
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0The Rosen Law Firm, P.A.
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0275 Madison Avenue, 40th Floor
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0New York, NY 10016
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Tel: (212) 686-1060
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Toll Free: (866) 767-3653
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Fax: (212) 202-3827
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0case@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0www.rosenlegal.com<\/a><\/p>\n